NO20073590L - Preventivt eller terapeutisk middel for sovnforstyrrelser - Google Patents

Preventivt eller terapeutisk middel for sovnforstyrrelser

Info

Publication number
NO20073590L
NO20073590L NO20073590A NO20073590A NO20073590L NO 20073590 L NO20073590 L NO 20073590L NO 20073590 A NO20073590 A NO 20073590A NO 20073590 A NO20073590 A NO 20073590A NO 20073590 L NO20073590 L NO 20073590L
Authority
NO
Norway
Prior art keywords
sleep
therapeutic agent
preventive
sleep disorders
disorders
Prior art date
Application number
NO20073590A
Other languages
English (en)
Inventor
Keisuke Hirai
Massaomi Miyamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36587809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073590(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20073590L publication Critical patent/NO20073590L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Det beskrives en kombinasjon av (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)etyl]propionamid med en medisin i stand til å forlenge langsombølge-søvntiden som gir et preventivt eller terapeutisk middel mot søvnforstyrrelser som induserer naturlig søvn, forkorter søvnlatens, øker dyp søvn, bibeholder søvnvarigheten og sikrer en egnet søvntid.
NO20073590A 2004-12-13 2007-07-11 Preventivt eller terapeutisk middel for sovnforstyrrelser NO20073590L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004359487 2004-12-13
PCT/JP2005/022756 WO2006064754A1 (ja) 2004-12-13 2005-12-12 睡眠障害予防治療剤

Publications (1)

Publication Number Publication Date
NO20073590L true NO20073590L (no) 2007-09-03

Family

ID=36587809

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073590A NO20073590L (no) 2004-12-13 2007-07-11 Preventivt eller terapeutisk middel for sovnforstyrrelser

Country Status (17)

Country Link
US (1) US20080242682A1 (no)
EP (1) EP1832286A4 (no)
JP (1) JPWO2006064754A1 (no)
KR (1) KR20070085973A (no)
CN (1) CN101076328A (no)
AR (1) AR052152A1 (no)
AU (1) AU2005314935A1 (no)
BR (1) BRPI0519016A2 (no)
CA (1) CA2590838A1 (no)
IL (1) IL183520A0 (no)
MA (1) MA29085B1 (no)
MX (1) MX2007006825A (no)
NO (1) NO20073590L (no)
PE (1) PE20060745A1 (no)
RU (1) RU2007126638A (no)
TW (1) TW200626137A (no)
WO (1) WO2006064754A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1937265A2 (en) * 2005-08-19 2008-07-02 Aventis Pharmaceuticals Inc. Comination of a hypnotic agent and r(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenl)ethyl]-4-piperidinemethanol and therapeutic application thereof
FR2889811B1 (fr) * 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
WO2009082268A2 (ru) 2007-12-21 2009-07-02 Alla Chem, Llc ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
US20120108669A1 (en) * 2008-11-13 2012-05-03 Sanofi-Aventis Method of treating sleep disorders using eplivanserin
EP2266554A1 (en) * 2009-05-26 2010-12-29 Sanofi-Aventis Method of treating sleep disorders using eplivanserin
EP2255726A1 (en) * 2009-05-26 2010-12-01 Sanofi-Aventis Spectral profile of SWS enhancing drugs
EP2269600A1 (en) * 2009-07-02 2011-01-05 Sanofi-Aventis Treatment of sleep disorders using eplivanserin in COPD patients
US9526718B2 (en) 2011-06-28 2016-12-27 Vivozon, Inc. Combination of effective substances causing synergistic effects of multiple targeting and use thereof
WO2021205648A1 (ja) * 2020-04-10 2021-10-14 国立大学法人東海国立大学機構 精神障害患者の客観的睡眠評価方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0885210B2 (en) * 1996-03-08 2008-06-18 Takeda Pharmaceutical Company Limited Tricylic compounds having binding affinity for melatonin receptors, their production and use
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JP4081161B2 (ja) * 1997-09-05 2008-04-23 武田薬品工業株式会社 光学活性化合物の製造法
AU4060599A (en) * 1998-06-09 1999-12-30 Takeda Chemical Industries Ltd. Pharmaceutical composition for treating or preventing sleep disorders
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
WO2003059349A1 (en) * 2002-01-10 2003-07-24 Biovail Laboratories Inc. Sedative non-benzodiazepine formulations
US20030165566A1 (en) * 2002-01-10 2003-09-04 O'toole Edel Sedative non-benzodiazepine formulations
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
AU2004308962A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
FR2889811B1 (fr) * 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.

Also Published As

Publication number Publication date
US20080242682A1 (en) 2008-10-02
TW200626137A (en) 2006-08-01
KR20070085973A (ko) 2007-08-27
EP1832286A4 (en) 2009-11-18
AU2005314935A1 (en) 2006-06-22
MX2007006825A (es) 2007-07-25
BRPI0519016A2 (pt) 2008-12-23
CA2590838A1 (en) 2006-06-22
EP1832286A1 (en) 2007-09-12
PE20060745A1 (es) 2006-09-05
MA29085B1 (fr) 2007-12-03
AR052152A1 (es) 2007-03-07
IL183520A0 (en) 2007-09-20
CN101076328A (zh) 2007-11-21
JPWO2006064754A1 (ja) 2008-06-12
WO2006064754A1 (ja) 2006-06-22
RU2007126638A (ru) 2009-01-20

Similar Documents

Publication Publication Date Title
NO20073590L (no) Preventivt eller terapeutisk middel for sovnforstyrrelser
AR043188A1 (es) Metodos y composiciones para el tratamiento de enfermedades y trastornos asociados con niveles elevados de citoquinas proinflamatorias
NO20050607L (no) Fremgangsmate og innretning for tildeling av CO
DK1694318T3 (da) (S)-2-N-propylamino-5-hydroxytetralin som D3-agonistisk terapeutikum
HUP0303083A2 (hu) CETP-gátló és atorvasztatin terápiás kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk
NO20055152D0 (no) Karbonstyrilderivater og humor stabiliserende midler for behandling av humor forstyrrelser
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
CY1109229T1 (el) Χρηση σπογγοσινης (2-μεθοξυαδενοσινης) για τη θεραπεια πονου, συγκεκριμενα υπερευαισθησιας στο πονο
DK1781277T3 (da) Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol
IL169358A (en) A pharmaceutical formulation containing aripiprazole or its metabolite and serotonin reuptake inhibitors for the preparation of a medication to treat mood disorders
ITRM20050514A1 (it) Olio ozonizzato, principio attivo di elevata stabilita&#39; a base di perossidi utilizzabile per applicazioni terapeutiche mediche e per trattamenti domiciliari similari a quelli dell&#39;ozonoterapia, senza l&#39;utilizzo di ozono gassoso.
UA84697C2 (ru) Использование (1s,2r) энантиомера милнаципрана для получения лекарственного средства
DK1784173T3 (da) Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater
CL2009000980A1 (es) Uso de (s)-n-(2-(1,6,8-tetrahidro-2h-inden[5,4-b]furan-8-il)etil]propionamida en combinacion con una o más drogas seleccionadas de un grupo definido para preparar un medicamento útil para la prevencion o tratamiento de la depresión o desórdenes de ansiedad (divisional de la solicitud 749-2006).
TW200509896A (en) Analeptic and drug combinations
HRP20050579B1 (hr) Nove sinergistiäśne kombinacije koje sadrže roflumilast i formoterol
DK1614419T3 (da) Midler til forebyggelse/behandling af retinale nervesygdomme, indeholdende alkyletherderivater eller salte deraf
DK1478362T3 (da) Kombinationsbehandling til akut myokardisk infarkt
AR023452A1 (es) Utilizacion del osanetant para preparacion de medicamentos utiles en el tratamiento de los trastornos del humor
NO20073610L (no) Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase
DE60322577D1 (de) Tablette enthaltend efletirizin und pseudoephedrin
AR056076A1 (es) Agente profilactico o terapeutico para el desorden de sueno
AR054246A1 (es) Agente profilactico o terapeutico para desorden de conducta nocturno asociado con demencia
NO20050933L (no) Pravastatin farmasoytiske formuleringer og fremgangsmater for anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application